Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal antithrombotic strategy in atrial fibrillation patients with ACS or PCI
2022-001298-30Phase 4Active
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of edoxaban in Atrial fibrillation (AFib), coronary arteriosclerosis and acute coronary syndrome (ACS) (2 arms), sponsored by St. Antonius Ziekenhuis. Started Jun 2022; status: active.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)coronary arteriosclerosisacute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2022-001298-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001298-30.